Table 3.
Relationship between pneumococcal vaccination status and pneumococcal carriage in children with cancer.a,b
| Vaccinated with PCV7 (n = 58) | Not vaccinated against pneumococcus (n = 216) | OR (95% CI) | |
|---|---|---|---|
| Pneumococcal carrier status | |||
| Any serotype | |||
| Non-carriers | 39 (67.2) | 183 (84.7) | 1 (reference) |
| Carriers | 19 (32.8) | 33 (15.3) | 1.70 (0.79-3.65) |
| Serotypes in PCV7 | |||
| Non-carriers | 43 (74.1) | 190 (88.0) | 1 (reference) |
| Carriers | 15 (25.9) | 26 (12.0) | 1.51 (0.65-3.49) |
| Six additional serotypes in PCV13 | |||
| Non-carriers | 53 (91.4) | 211 (97.7) | 1 (reference) |
| Carriers | 5 (8.6) | 5 (2.3) | 2.69 (0.62-11.7) |
| Subgroup aged | (n = 39) | (n = 85) | |
| Any serotype | |||
| Non-carriers | 22 (56.4) | 67 (78.8) | 1 (reference) |
| Carriers | 17 (43.6) | 18 (21.2) | 2.05 (0.81-5.20) |
| Serotypes in PCV7 | |||
| Non-carriers | 25 (64.1) | 71 (83.5) | 1 (reference) |
| Carriers | 14 (35.9) | 14 (16.5) | 1.79 (0.66-4.91) |
| Six additional serotypes in PCV13 | |||
| Non-carriers | 34 (87.2) | 83 (97.6) | 1 (reference) |
| Carriers | 5 (12.8) | 2 (2.4) | 4.33 (0.63-29.5) |
| Subgroup aged 10-14 years | (n = 14) | (n = 86) | |
| Any serotype | |||
| Non-carriers | 13 (92.9) | 75 (87.2) | 1 (reference) |
| Carriers | 1 (7.1) | 11 (12.8) | 0.76 (0.08-7.47) |
| Serotypes in PCV7 | |||
| Non-carriers | 14 (100.0) | 78 (90.7) | 1 (reference) |
| Carriers | 0 (0.0) | 8 (9.3) | NE |
| Six additional serotypes in PCV13 | |||
| Non-carriers | 14 (100.0) | 84 (97.7) | 1 (reference) |
| Carriers | 0 (0.0) | 2 (2.3) | NE |
a
ORs adjusted for age at enrollment, gender, siblings, parental smoking, disease phase, co-trimoxazole prophylaxis and diagnosis.
b
No information concerning the pneumococcal vaccination status of three children.
CI: confidence interval; NE: not estimable; OR: odds ratio; PCV7: 7-valent pneumococcal conjugate vaccine; PCV13: 13-valent pneumococcal conjugate vaccine.